MedTrace Logo

Early Prediction of Oral Cancer by S100A7 Immunohistochemistry Signature-based Assessment

NCT04622462 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2024-11-07

No results posted yet for this study

Summary

The purpose of this observational study is to evaluate the utility of the S100A7 immunohistochemistry signature-based assessment - STRATICYTE - in determining the risk of progression to cancer of clinically suspicious oral lesions.

Conditions

  • Oral Neoplasm

Interventions

PROCEDURE

Standard of Care Histopathology

Assessment for mild, moderate, or severe dysplasia, and risk of progression to oral cancer

PROCEDURE

STRATICYTE Assessment

Assessment for risk of progression to oral cancer

Sponsors & Collaborators

  • Proteocyte Diagnostics Inc.

    lead INDUSTRY

Principal Investigators

  • Mark Darling, MSc, MChD · Western University

Eligibility

Min Age
15 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-12
Primary Completion
2025-12-31
Completion
2026-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04622462 on ClinicalTrials.gov